Repligen's 0.25% debt comes with a bigger repayment bill

Repligen is paying investors with a bigger promise to repay. Under a financing agreement announced October 30, holders will exchange about $456.8 million of existing notes for $541.4 million of new ones.

The bioprocessing equipment supplier gets a lower annual interest rate and more time. The new notes pay 0.25% and mature in 2031, replacing debt that pays 1% and falls due in 2028. The exchange adds $84.6 million, or about 18.5%, to the principal being swapped, meaning the amount to be repaid.

That tradeoff is the most revealing part of a $1 billion convertible-note transaction. The other $458.6 million of new notes will be sold for cash. Repligen expects the transaction to close around November 6.

A smaller interest check, a larger balance

After the transaction, Repligen would have $1 billion of new notes plus $143.2 million of old notes left outstanding. Together, that is about $1.14 billion to repay, compared with $600 million of existing principal.

The lower rate still reduces the regular annual cash interest bill. Based on the announced terms, it falls from about $6 million to $3.9 million across both sets of notes. But the exchange also increases the amount owed, so the interest rate alone gives an incomplete picture of the cost.

Investors receive conversion rights as well. If they convert, Repligen must pay the principal in cash; any value above that can be paid in cash, shares or a combination. That creates a possible source of future shareholder dilution.

The financing follows a large acquisition

Repligen completed its roughly $1.9 billion acquisition of BioLife Solutions on October 6, expanding its tools for making and handling cell therapies. It issued about 7.2 million shares and paid about $564 million from existing cash.

Its September balance sheet showed $863 million of cash and marketable securities, before that acquisition payment. The new financing adds flexibility after the deal while moving most of the old debt's maturity further out.

Some of the fresh cash will immediately return to shareholders. Repligen plans to spend about $120 million buying stock from participating investors to facilitate the financing. That leaves roughly $339 million before fees from the cash subscription for working capital and other corporate uses, including possible future deals.

The Repligen company profile follows the completed deal, operating results and financing terms.